|
EQS-News: ABIVAX / Key word(s): Half Year Report Abivax announces the release of its 2023 half-year financial report 29.09.2023 / 18:00 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax announces the release of its 2023 half-year financial report PARIS, France, September 29, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announces today the release of its 2023 half-year financial report. The 2023 half-year financial report is available on the website of the Company (www.abivax.com – “Investors”). About Abivax Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Based in France and the U.S., Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com. Follow us on X, formerly Twitter, @ABIVAX_. Contacts
29.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Novartis’ radiopharma gambit; Weight loss battle plays out; Spark co-founder’s new startup; Q1 earnings highlights; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit
May 5, 2024